Skip to main content
Figure 5 | Molecular Pain

Figure 5

From: ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response

Figure 5

Effect of ARA 290 on Iba-1 immunoreactivity after spared nerve injury. Quantification graphs showing Iba-1 immunoreactivity (percentage of immunostained area) in sections of different lumbar spinal cord levels (L1-L6) from animals 2 weeks (panel A) or 20 weeks (panel B) after sham-operation (grey), spared nerve injury and vehicle-treated (red), spared nerve injury and treatment with 10 μg/kg ARA 290 (green), or spared nerve injury and treatment with 30 μg/kg ARA 290 (marine blue). At 2 weeks post injury (A), Iba-1-IR was increased in the L5 segment following vehicle treatment only (grey box p < 0.05 vs. sham). At 20 weeks post injury (B), vehicle p < 0.05 vs. sham at segments L2-L5) and 10 μg/kg: p < 0.05 vs. sham at segments L2-L4 (grey boxes). Data are mean ± SEM.

Back to article page

Molecular Pain

ISSN: 1744-8069

Contact us